{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:29:08Z","timestamp":1793464148433,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>As the life expectancy of people living with human immunodeficiency virus (HIV) (PLWH) has improved, chronic disease burden and polypharmacy have increased in PLWH. Simplification of the antiretroviral therapy (ART) regimen for PLWH has become crucial. The real-world treatment patterns and medication persistence of the 2-drug single-tablet regimen (STR), dolutegravir\/lamivudine (DTG\/3TC), compared to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) prescribed were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, database study extracted data from a hospital-based medical claims database in Japan. The changes in ART distributions by year during the identification period between January 1, 2018 and December 31, 2021 were observed. Patients with disease record of HIV-1 infection and prescribed DTG\/3TC or BIC\/FTC\/TAF as the first prescription of STR during the identification period were divided into two cohorts; DTG\/3TC cohort and BIC\/FTC\/TAF cohort, respectively. Patient without medication records more than 3 months and no future data more than 6 months were excluded. Patients\u2019 characteristics were compared between the DTG\/3TC cohort and the BIC\/FTC\/TAF cohort by Mantel\u2013Haenszel test to adjust for age. Medication persistence was compared between the two cohorts by evaluating the continuation rates using Kaplan\u2013Meier methods, using the log-rank test to assess the difference between the Kaplan\u2013Meier curves. The median time-to-first prescription was compared between the two cohorts by Kaplan\u2013Meier methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prescriptions of DTG\/3TC and BIC\/FTC\/TAF increased steadily from 2019 to 2021 after the release year of each STR. There was no significant difference in the time-to-first prescription (<jats:italic>p<\/jats:italic>\u2009=\u20090.3). A total of 959 patients were included, with 120 patients and 839 patients on DTG\/3TC and BIC\/FTC\/TAF, respectively. The proportion of dyslipidemia at baseline was significantly higher in the DTG\/3TC cohort than in the BIC\/FTC\/TAF cohort after adjusting for mean age (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). There was no significant difference in medication persistence between the two cohorts (<jats:italic>p<\/jats:italic>\u2009=\u20090.91).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study showed that DTG\/3TC was likely to be selected for elderly patients and those with chronic disease in real-world clinical practice, which seems in accordance with the treatment strategy recommended by guidelines. Comparable medication persistence was observed with both regimens, aligning with findings from other countries. The 2-drug single-tablet regimen DTG\/3TC may be an important ART regimen for PLWH with multiple morbidities and polypharmacy in an aging society. Due to the limitations of the database, further research to assess viral loads, emergence of resistance and adverse events will be encouraged.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1329922","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:30:48Z","timestamp":1725942648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and real-world medication persistence of people living with HIV treated with DTG\/3TC or BIC\/FTC\/TAF: a hospital claims database study in Japan"],"prefix":"10.3389","volume":"11","author":[{"given":"Rie","family":"Kanamori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohide","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"North American AIDS cohort collaboration on research and design (NA-ACCORD) of IeDEA. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/s2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e019985","DOI":"10.1136\/bmjopen-2017-019985","article-title":"Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database","volume":"8","author":"Ruzicka","year":"2018","journal-title":"BMJ Open"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/hiv.13206","article-title":"Comorbidities and co-medications among 28 089 people living with HIV: a nationwide cohort study from 2009 to 2019 in Japan","volume":"23","author":"Naito","year":"2022","journal-title":"HIV Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s12879-019-4129-6","article-title":"Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database","volume":"19","author":"Ruzicka","year":"2019","journal-title":"BMC Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41598-022-05816-5","article-title":"Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan","volume":"12","author":"Naito","year":"2022","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad101","article-title":"Sustained virologic suppression with dolutegravir\/lamivudine in a test-and-treat setting through 48 weeks. Open forum","author":"Rolle","year":"2023","journal-title":"Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide\u2013based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.2147\/idr.s375439","article-title":"The emergence of resistance under firstline INSTI regimens","volume":"15","author":"Xie","year":"2022","journal-title":"Infect Drug Resist"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40121-022-00630-y","article-title":"Shorter time to discontinuation due to treatment failure in people living with HIV switched to dolutegravir plus either rilpivirine or lamivudine compared with integrase inhibitor-based triple therapy in a large Spanish cohort","volume":"11","author":"Teira","year":"2022","journal-title":"Infect Dis Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1186\/s12889-024-18774-6","article-title":"Factors associated with antiretroviral treatment adherence among people living with HIV in Guangdong Province, China: a cross sectional analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Public Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"ref17","first-page":"138","volume-title":"Pharma Japan 2023 Handbook","year":"2023"},{"key":"ref18","year":"2013"},{"key":"ref19","year":"2013"},{"key":"ref20","year":""},{"key":"ref21","year":""},{"key":"ref22","year":"2023"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40121-023-00848-4","article-title":"Comparing real-world healthcare costs associated with single-tablet regimens for HIV-1: the 2-drug regimen dolutegravir\/lamivudine vs. standard 3- or 4-drug regimens","volume":"12","author":"Priest","year":"2023","journal-title":"Infect Dis Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12879-021-06991-y","article-title":"Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection","volume":"22","author":"Deng","year":"2022","journal-title":"BMC Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/v14112558","article-title":"Real-world effectiveness, tolerability, and safety of dolutegravir\/lamivudine in Korea","volume":"2558","author":"Lee","year":"2022","journal-title":"Viruses"},{"key":"ref27","article-title":"What influences switching to DTG\/3TC vs B\/F\/TAF in clinical practice?","author":"Paul","year":"2023"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s40121-023-00879-x","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide versus Dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: a real-world cohort study","volume":"12","author":"Gan","year":"2023","journal-title":"Infect Dis Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0291480","DOI":"10.1371\/journal.pone.0291480","article-title":"Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults","volume":"18","author":"Mendoza","year":"2023","journal-title":"PLoS One"},{"key":"ref31","first-page":"122","article-title":"Changes in clinical data after switching from 3 antiretroviral drugs to dolutegravir\/lamivudine","volume":"23","author":"Konishi","year":"2021","journal-title":"J AIS Res."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12981-023-00507-1","article-title":"An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor\u2013based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1","volume":"20","author":"Evitt","year":"2023","journal-title":"AIDS Res Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1089\/AID.2020.0219","article-title":"Short communication: comparing lamivudine+Dolutegravir and Bictegravir\/Emtricitabine\/Tenofovir Alafenamide as switch strategies: preliminary results from clinical practice","volume":"37","author":"Baldin","year":"2021","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s12325-023-02459-4","article-title":"Safety and effectiveness analyses of dolutegravir\/lamivudine in patients with HIV: 2-year report of post-marketing surveillance in Japan","volume":"40","author":"Tofukuji","year":"2023","journal-title":"Adv Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1038\/s41598-018-22914-5","article-title":"Analyses of HIV-1 integrase sequences prior to south African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa","volume":"8","author":"Brado","year":"2018","journal-title":"Sci Rep"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/AAC.06170-11","article-title":"Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens","volume":"56","author":"Garrido","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J Antimicrob Chemother"}],"updated-by":[{"DOI":"10.3389\/fmed.2025.1555353","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1329922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:37:18Z","timestamp":1738946238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1329922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":37,"alternative-id":["10.3389\/fmed.2024.1329922"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1329922","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2025.1555353","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"article-number":"1329922"}}